P VIII 101
Alternative Names: P-FVIII-101; P-VIII-101Latest Information Update: 14 Mar 2024
At a glance
- Originator Poseida Therapeutics
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Factor VIII replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haemophilia A
Most Recent Events
- 07 Mar 2024 Adverse events data from a preclinical trial in Haemophilia A released by Poseida Therapeutics
- 18 May 2023 Pharmacodynamics data from preclinical studies in Hemophilia A released by Poseida Therapeutics
- 11 Dec 2022 Preclinical pharmacodynamic data in Haemophilia A released by Poseida Therapeutics